Open Surgery Heart Valve Market Snapshot
“The Open Surgery Heart Valve Market to grow from USD 4530 Million in 2023 to USD 10890 Million by 2030, at a CAGR of 12%.”
Open heart surgery is a common procedure for replacing or repairing heart valves, using a sternotomy to open the chest, allowing surgeons easy access to the heart valve(s) and chest.
Open heart surgery can take up to two hours and take a few weeks for recovery. However, some valvar heart disease can benefit from less invasive, recent minimally invasive operations, which may require a small incision beneath the right pectoral muscle in the chest or breastbone.
Healthcare professionals may diagnose a defective valve or valves needing surgical repair or replacement based on symptoms and overall heart state.
Open heart valve surgery is typically the best option for patients with valve disorders untreatable with medicine.
A multidisciplinary team of skilled surgeons and cardiac imaging specialists will repair the valve, avoiding infection, long-term blood thinner use, and other potential complications, rather than replacing it.
Heart valve disease is a condition where one or more heart valves fail to open and close properly, making it harder for the heart to pump blood. It can develop later in life due to infections, aging, calcific degeneration, heart attacks, heart disease, or traumas, or can be congenital.
The most common conditions that impair blood flow via valves are stenosis and regurgitation. Some valve problems are minor and don't require treatment, while others may require medication, lifestyle changes, or surgery.
>>>Download Sample Report Now:https://marketreportservice.com/request-sample/open-surgery-heart-valve-market-54707
Segment Analysis
Carbon and titanium are two common materials used to make mechanical heart valves. Usually, they are made out of two leaflets and a knitted fabric ring encircling a metal ring that is sewed onto the heart in place of the original valve.
Mechanical heart valves are categorized into three main types: tilting disc, bileaflet, and caged ball valves. The Starr-Edwards valve is the only FDA-approved caged ball valve.
Bioprosthetic valves, such as Hancock II and Mosaic valves (Medtronic) and Carpentier-Edwards valves (Edwards Lifesciences), are made using bovine pericardium or swine valves.
Artificial heart valves, also known as mechanical valves, are made from plastic or metallic alloys and are typically made from animal tissue and placed on a bioprosthesis frame.
Growth Drivers
The open surgery heart valves market faces challenges such as changing regulatory stringency, complex procedures, and high equipment and operating costs, which are affecting revenue growth to some extent.
Bioprosthetic valves are commonly used to maintain pulmonary valve function after CHD surgery, but their failure may necessitate their reoperation.
The global open surgery heart valves market is growing due to factors such as the aging population, structural heart disease, investment in heart valve therapies, advances in diagnostic technology, high diagnosis rates, public awareness of new treatment options, and increasing prevalence of congenital heart defects and other cardiovascular diseases.
The high consumption of saturated trans-fat foods and government campaigns to raise public awareness are expected to increase demand for these treatments worldwide.
Market Restraints
The open surgery heart valves market faces challenges such as changing regulatory stringency, complex procedures, and high equipment and operating costs, which are affecting revenue growth to some extent.
Opportunities
Companies in the heart valve market are focusing on R&D to improve safety and effectiveness of heart valve procedures. They are introducing new, technologically advanced equipment, leading to the development of minimally invasive surgical techniques.
A new approach called transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve implantation (TAVI) has received FDA approval for patients with symptomatic Aortic Stenosis at high risk of traditional valve replacement surgery.
Acquisitions are also a key strategy for market positioning and product innovation.
Competitive Landscape of the Open Surgery Heart Valve Market Analysis
New Developments in Open Surgery Heart Valve Market
September 28, 2020- Boston Scientific Launches ACURATE neo2™ Aortic Valve System in Europe
Boston Scientific Corporation announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with a number of features to improve upon the clinical performance of the original ACURATE neo platform.
CryoLife Pays $130M for On-X Life's Mechanical Heart Valve Business
Atlanta-based CryoLife, a medical device company specializing in cardiac and vascular surgery, has announced plans to acquire On-X Life Technologies (On-X) and its portfolio of mechanical heart valves in a deal worth $130 million. While some question CryoLife’s late entry into the heart valve business, CryoLife’s CEO highlighted On-X’s recent FDA approvals and potential to grow with CryoLife’s sales team support.
Regional Analysis of Global Open Surgery Heart Valve Industry
The open surgery heart valves market in Asia Pacific is expected to rapidly grow due to rising healthcare costs, government initiatives, and rapid development of healthcare infrastructure in developing nations like China and India.
Additionally, the increasing incidence of chronic and lifestyle-related diseases is also a favorable factor for market expansion.
In terms of revenue, North America is second after Europe for the aortic valve replacement market. North America is predicted to expand at a rate of 11.7% over the next several years and is recognized for having the most sophisticated healthcare facilities.
Segments Covered in the Open Surgery Heart Valve Market Report
Open Surgery Heart Valve Market Segment by Product Types
- Mechanical Heart Valves
- Bioprosthetic Heart Valves
Open Surgery Heart Valve Market Segment by End-Users
- Hospitals
- Cardiac Surgery Centers
Open Surgery Heart Valve Market Segment by Procedures
- Closure of Atrial Septal Defect (ASD)
- Closure of Ventricle Septal Defect (VSD)
Open Surgery Heart Valve Market Segment by Color Visualization
- Transesophageal Echocardiography (TEE)
- Intraoperative Fluoroscopy
Open Surgery Heart Valve Market by Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Frequently Asked Questions
What are some applications of Open Surgery Heart Valve?
Open-heart surgery is used to treat a range of heart conditions, including: Heart failure, Heart valve disease, Arrhythmias, Aneurysms, Coronary artery disease.
What is the expected growth rate of the Open Surgery Heart Valve market over the next 7 years?
Open Surgery Heart Valve Market to grow from USD 4530 Million in 2023 to USD 10890 Million by 2030, at a CAGR of 12%.
Who are the major players in the Open Surgery Heart Valve market and what is their market share?
Abbott Vascular Inc., Arterius Ltd, Cardionovum GmbH, Aneuclose LLC, Inspire MD, Boston Scientific Corporation, Japan Stent Technology Co, Gaudi Vascular, Microvention, Edwards Lifesciences Corporation, CryoLife, are prominent players operating and dominating in the market.
Who are the top 3 Open Surgery Heart Valve Market Key Vendors?
Abbott Vascular Inc., Arterius Ltd, Cardionovum GmbH, are key players in the Open Surgery Heart Valve market.
Which geographical areas dominate the worldwide market for Open Surgery Heart Valve?
Asia Pacific region are emerging as the top regional markets for Open Surgery Heart Valve solutions.
1.SUMMARY
1.1. Open Surgery Heart Valve Market Overview
1.2. Key Insights
1.3. Report Scope
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
- DECISION-MAKING SUMMARY
- INTRODUCTION
3.1. Overview of Open Surgery Heart Valve
3.2. Key Historical Events
3.3. Structure
3.4. Biochemical Interaction
3.5. Target Indications
3.6. Advantages of Open Surgery Heart Valve
3.7 Challenges associated with Open Surgery Heart Valve
3.8. Future Perspectives.
- MARKET LANDSCAPE
4.1. Methodology
4.2 Open Surgery Heart Valve: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.2.6. Most Active Players
- COMPANY
5.1. Company Overview
5.1.2 Management Team
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
- PARTNERSHIPS AND COLLABORATIONS
6.1. Partnership Models
6.2. Open Surgery Heart Valve: Partnerships and Collaborations
6.2.1. Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Analysis by Type of Partner
6.2.5. Analysis by Year of Partnership and Type of Partner
6.2.6. Analysis by Type of Partnership and Type of Partner
6.2.7. Analysis by Type of Partner and Parent Company Size
- ACADEMIC GRANTS ANALYSIS
7.1. Methodology and Key Parameters
7.2. Open Surgery Heart Valve: Academic Grants Analysis
7.2.1. Analysis by Year of Grant Award
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Funding Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Funding Institute Center and Support Period
7.2.6. Analysis by Type of Grant Application
7.2.7. Analysis by Purpose of Grant
- PUBLICATION ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Open Surgery Heart Valve: Publication Analysis
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Publication
8.2.3. Analysis by Type of Conjugate
8.2.4. Analysis by Target Indication
8.2.5. Analysis by Copyright Holder
8.2.6. Word Cloud: Emerging Focus Area
8.2.7. Most Active Publishers: Analysis by Number of Publications
- SUCCESS PROTOCOL ANALYSIS
9.1. Methodology and Key Parameters
9.2. Key Assumptions and Scoring Criteria
9.3. Success Protocol Analysis
9.4. Assessment of Approved Open Surgery Heart Valve
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies
- Abbott Vascular Inc.
- Arterius Ltd
- Cardionovum GmbH
- Aneuclose LLC
- Inspire MD
- Boston Scientific Corporation
- Japan Stent Technology Co
- Gaudi Vascular
- Microvention
- Edwards Lifesciences Corporation
- CryoLife
